Optimal duration of dual antiplatelet therapy following percutaneous coronary intervention: protocol for an umbrella review

Abstract

IntroductionAlthough dual antiplatelet therapy (DAPT) is routinely given to patients after percutaneous coronary intervention (PCI) with stenting, the optimal duration is unknown. Recent evidence indicates there may be benefits in extending the duration beyond 12 months but such decisions may increase the risk of bleeding. Our objective is to provide a comprehensive overview of the literature for clinicians and policymakers via an umbrella review assessing the optimal duration of DAPT.Methods and analysisWe will perform a comprehensive search of the published and grey literature for systematic reviews involving randomised controlled trials (RCTs) assessing the optimal duration of DAPT following PCI with stenting. The intervention of interest is extended DAPT (beyond 12 months) compared with short-term DAPT (6–12 months). Studies will be selected for inclusion by two reviewers, and the quality will be assessed. The primary outcomes of interest are all-cause mortality and cardiovascular mortality. Secondary outcomes will be bleeding (major, minor and gastrointestinal), urgent target vessel revascularisation, major adverse cardiovascular events, myocardial infarction, stroke and stent thrombosis. Outcomes will be assessed while on DAPT and after withdrawal of DAPT. Data will be summarised with respect to the number of included RCTs, number of participants, effect estimates and heterogeneity. Data will be reported separately based on patient demographics, procedural parameters (eg, stent types, lesion complexity and concurrent disease) and clinical presentation (eg, acute coronary syndromes, infarct type).Ethics and disseminationOur umbrella review aims to provide a comprehensive overview of the benefits and harms associated with extending DAPT beyond 12 months following PCI with stenting. The results of this review will inform clinical and policy decisions regarding the optimal treatment duration and reimbursement of DAPT following PCI with stenting. Results will be disseminated through a peer-reviewed publication and conference presentations. Ethics approval is not required for this study.Trial registration numberCRD42016047735.

Direct Oral Anticoagulants: Probability of Recurrent Venous Thromboembolism and Bleeding Risk in an Obese Population

“…For a major bleed event the ISTH definition was used and defined as any bleed event requiring hospitalization and/or a blood transfusion. 7 Any bleed event included any event recorded by a medical provider including heavy menstruation or new nose bleeds.…”

The impact of testosterone in men’s health

“…In terms of physical pathology, sexual symptoms such as ED, low libido, and reduced nocturnal erectile phenomena have been shown to have a close inverse relationship with testosterone levels [23]. A metaanalysis of the effects of TRT on sexual function suggests improvement of ED, libido, and QOL [24].…”

Assistência perioperatória em pacientes submetidos a intervenção coronariana percutânea

“…Juntamente com os inibidores de proteína P2Y12, a DAPT participa das estratégias de redução de complicações dos periprocedimentos de ICP associado ao aumento da morbidade e mortalidade, como o IAM, e, geralmente, são administrados em pacientes que não receberam anticoagulação no préprocedimento (LEE; CAVENDER, 2019). (ELLIOTT et al, 2017). Entretanto, de acordo com Khan et al (2020), após uma ICP com stents farmacológicos, o uso da DAPT de curto prazo seguida de monoterapia com inibidor de P2Y12 reduz as taxas de maiores sangramentos.…”